Inverna Therapeutics ApS: Financial statements 2025
CVR: 45161641
Source: annual report 2025, Danish Business Authority
01/01/2025 – 31/12/2025
Inverna Therapeutics ApS (CVR 45161641) has filed annual accounts for 2025. In 2025, the company reported a gross profit of DKK -14,150,019 and a net result of DKK -11,245,984. Equity in the 2025 report amounted to DKK 3,813,671. The solvency ratio was 54.9%. The company had 1 employee in the financial year.
- Gross Profit
- DKK -14,150,019
- Profit/Loss
- DKK -11,245,984
- Equity
- DKK 3,813,671
- Total Assets
- DKK 6,948,571
- Employees
- 1
Official annual report
How creditworthy is Inverna Therapeutics ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2025
As of December 1, 2025, Thomas Koed Doktor is registered as an owner of Inverna Therapeutics ApS with an ownership share of 5%.
As of December 1, 2025, Brage Storstein Andresen is registered as an owner of Inverna Therapeutics ApS with an ownership share of 10%.
As of December 1, 2025, is registered as an owner of Inverna Therapeutics ApS with an ownership share of 50%.
Inverna Therapeutics ApS has published its interim report for the period October 22, 2024 to December 31, 2024.
About Inverna Therapeutics ApS
Inverna Therapeutics ApS is a Danish company of the type Anpartsselskab based in Odense M, founded in 2024. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Poul Sørensen. The board consists of Poul Sørensen (chair), Brage Storstein Andresen, Daniel Sobral and Jens Kristian Damsgaard. The company's owners include Thomas Koed Doktor, Brage Storstein Andresen and SCIENCE VENTURES DENMARK A/S. According to the 2025 annual report, the company had an average of 1 employee. In 2025, the company reported a gross profit of DKK -14,150,019 and a net result of DKK -11,245,984. Equity in the 2025 report amounted to DKK 3,813,671.